Title: Evaluation of nanopore sequencing on polar bodies for routine preimplantation genetic testing for aneuploidy.

Running Title: Nanopore polar body aneuploidy screening

Authors:

Anna Oberle¹, Franziska Hanzer¹, Felix Kokocinski², Anna Ennemoser¹, Luca Carli¹,

Enrico Vaccari¹, Markus Hengstschläger¹, Michael Feichtinger^{1*}

Affiliation:

¹ Wunschbaby Institut Feichtinger, Lainzer Straße 6, 1130 Vienna, Austria

² Gene-Test Bioinformatics Solutions, Jakob-Müller-Str. 16, 68623 Lampertheim, Germany

***Corresponding author:** Michael Feichtinger, <u>michael.feichtinger@wunschbaby.at</u>, +43 1 8777775, Lainzerstrasse 6, 1130 Vienna, Austria

Keywords: PGT-A, Polar Body Biopsy, Nanopore Sequencing, Oxford Nanopore Technology, Cost effective PGT-A

Structured Abstract:

BACKGROUND

PGT-A using polar body (PB) biopsy derives a clinical benefit by reducing the number of embryo transfers and miscarriage rates but is currently not cost-efficient. Nanopore sequencing technology opens possibilities by providing cost-efficient, fast sequencing results with uncomplicated sample preparation workflows.

METHODS

In this comparative experimental study, 102 pooled PB samples from 20 patients were analyzed for aneuploidy using nanopore sequencing technology and compared with aCGH results generated as part of the clinical routine. Samples were sequenced on a Nanopore MinION machine for up to 9 hours for 6 pooled PB samples. Whole-chromosome copy-numbers were called by a custom bioinformatic analysis software. Automatically called results were compared to aCGH results.

RESULTS

Overall, 96/99 samples were consistently detected as euploid or aneuploid in both methods (concordance=97.0%, sensitivity = 0.957, specificity = 1.0, PPV = 1.0, NPV = 0.906). On chromosomal level, concordance reached 98.7%. Chromosomal aneuploidies analyzed in this trial covered all 23 chromosomes with 98 trisomies, and 97 monosomies in 70 aCGH samples.

The whole nanopore workflow is feasible in under 5 hours (for one sample) with maximum time of 16 hours (for 12 samples), enabling fresh PB-euploid embryo transfer. Material cost of 150€/sample possibly enable cost-efficient aneuploidy screening.

CONCLUSIONS

This is the first study, systematically comparing nanopore sequencing for aneuploidy of PBs with standard detection methods. High concordance rates confirmed feasibility of nanopore technology for this application. Additionally, the fast and cost-efficient workflow reveals clinical utility of this technology, making PB PGT-A clinically attractive.

1 Introduction

2 With increasing female age, the probability for an uploid embryos increases and with 3 it the risk of age-related infertility, abortions and children born with aneuploidies (1). 4 Early pregnancy loss and spontaneous abortions are most frequently caused by chromosomal abnormalities of the embryo (2). In contrast to maternal age, paternal 5 6 age plays a minor role for chromosomal abnormalities (3). Preimplantation-genetic 7 testing for an euploidy (PGT-A) is used to screen for unbalanced chromosomal 8 distributions before implantation and can therefore reduce miscarriage rates and 9 improve pregnancy and life-birth rates per embryo-transfer, especially in patients with 10 advanced-maternal age (4,5).

11 DNA analyzed in PGT-A can originate from trophectoderm cells, blastomere cells or 12 polar bodies (PBs). All three sources have advantages and specific limitations. While 13 PB analysis allows the detection of meiotic maternal aneuploidies only, the analysis 14 of trophectoderm biopsy (TEB) and blastomere biopsy can detect embryogenic aneuploidies. However, blastomere biopsy can possibly damage the embryo (6,7) 15 and was shown to provide limited clinical benefit (8) and is therefore not commonly 16 17 performed anymore. In TEB analysis, which is currently seen as the gold standard for 18 PGT-A, diagnosed trophectoderm aneuploidies might differ from embryogenic 19 material of the inner cell mass due to mosaicisms (9). Embryos classified as 20 aneuploid or mosaic by TEB can lead to euploid, healthy life-births, indicating 21 discordances between inner cell mass and trophectoderm or self-repair mechanisms (10,11). 22

In contrast, PGT-A using PB biopsy leaves less room for interpretation, since mitotic
 errors in cell division leading to mosaicisms are not detected here. In a large
 multicenter randomized clinical trial ('ESHRE Study into the Evaluation of oocyte

26 Euploidy by Microarray analysis', ESTEEM trial), PGT-A using PB was shown to 27 significantly reduce the number of embryo transfer needed for live birth, reduce 28 number of cryopreserved embryos and reduce miscarriage rates (12). These findings highlight the clinical benefit for PGT-A using PB. In contrast to PGT-A using TEB, PB 29 30 biopsy allows fresh embryo transfer and can avoid freeze-all procedures. 31 Additionally, due to legal restrictions for TEB analysis in several European countries, 32 PB biopsy is often the only option and is performed frequently in countries like 33 Germany or Austria (13,14).

However, PB analysis was previously stated to be not cost effective (15,16). Lowering the cost for PB-based PGT-A and PGT-A in general is therefore an important goal to improve patient acceptance and accessibility.

PGT-A is often performed using short-read next-generation sequencing (NGS), which requires high initial investment costs and high running expenses. Third-generation sequencing using nanopores is a novel technology with the potential to perform sequencing in a fast, easy, and cost-effective way, enabling application even in small and less well-financed clinics (17). Continuous development of the technology led to significant improvements in sequencing quality (18,19).

43 Feasibility of nanopore sequencing for PGT was mainly shown for structural variants 44 and monogenetic disease (20–24), which comes with high costs and is far from 45 clinical routine (22). PGT-A from TEB samples using nanopore sequencing was first 46 demonstrated in a small pilot study (25). A follow-up study compared their optimized 47 nanopore aneuploidy analysis of 52 chorionic villi samples, 50 amniotic fluid samples, 48 64 placental or fetal tissue samples and 52 TEB samples with standard NGS PGT-A 49 screening (26). Overall, the authors saw very good concordance rates. The optimized 50 nanopore workflow was notably faster (2-6 hours) and more cost-effective (around 50 US\$ sequencing cost per sample) compared to traditional NGS screening (26). In a recent study, single and multiple cells as well as 96 TEB samples were analyzed for PGT-A and segmental aneuploidies using nanopore sequencing, again confirming high concordance rates above 95% with commercial kits for PGT-A (27). However, further clinical studies are needed to transfer the technology into clinical PGT-A routine analysis.

In the present study, pooled PBs from 102 oocytes were analyzed using nanopore sequencing and compared to results generated as part of the clinical routine using array comparative genomic hybridization (aCGH). This is the first study that analyses aneuploidy from PB samples using nanopore sequencing technology including detailed cost analysis of the nanopore sequencing workflow.

62 Material and Methods

63 Study design and sampling:

In this comparative study, 102 pooled PB samples from 20 patients treated for infertility between March and December 2022 were prospectively collected and analyzed for aneuploidy using nanopore sequencing technology. Nanopore sequencing results were compared with aCGH results generated as part of the clinical routine. All patients participating in this trial were treated for infertility at 'Wunschbaby Institut Feichtinger' (WIF) in Vienna and chose aneuploidy screening of their polar bodies. All patients provided written informed consent. The study was approved by the Ethic Committee of the Medical University Vienna (EK-1249/2022). After oocyte pick-up and fertilization by intracytoplasmic sperm injection (ICSI), both PBs 1 and 2 were taken simultaneously 16 to 18 hours after fertilization and placed in one sterile PCR tube with 2.5 µl of fresh, sterile phosphate-buffered saline (PBS). Opening of the zona pellucida was performed using RI Saturn 5 ActiveTM (Research Instruments Ltd, UK). PB samples were frozen at -20°C and transported to an external genetic diagnostic laboratory for routine analysis.

64 DNA Amplification and reference analysis:

PGT-A routine analysis of pooled PBs was performed after the standard GentiSure Pre-Screen Kit for Single Cell Analysis Kit (Agilent Technologies, USA) protocol, including Whole Genome Amplification (WGA) with REPLI-g Single Cell Kit using a phi29 polymerase process (QIAGEN, Germany), Fluorescent Labeling and CGH Microarray. This standard protocol was adapted for PB diagnosis. Around 5µg of WGA aliquots from PB samples were anonymized and used for nanopore sequencing.

72 Nanopore Library Preparation:

After receiving anonymized WGA DNA samples, quality was confirmed by agarose gel electrophoresis (Thermo Fisher Scientific, USA) and quantity was measured by Qubit 4 fluorometer (Thermo Fisher Scientific, Singapore). Then WGA DNA was purified using gDNA Clean & Concentrator-25 columns (Zymo Research, USA).

As part of the protocol optimization, around 1.5 µg of purified DNA was prepared for some samples by digestion of single-stranded regions using T7 Endonuclease I (New England Biolabs (NEB), UK) to reduce or remove branched structures which were introduced during amplification. DNA was purified using gDNA Clean & Concentrator-25 columns (Zymo Research, USA) and eluted in 50µl nuclease-free water.

For library preparation, the Oxford Nanopore Technology (ONT, UK) Kits 'Ligation Sequencing Kit' (SQL-LSK109) and 'Native Barcoding Expansion' (EXP-NBD104) were used according to manufacturer's recommendations, as previously tested in a pre-clinical trial (28).

Briefly, 1 - 1.5 µg purified DNA was repaired and end-prepared using NEBNext® 86 87 FFPE DNA Repair and Ultra[™] II End-prep Mix (both from NEB, UK) and purified 88 using DNA Clean & Concentrator-5 columns (Zymo Research). For native barcode 89 ligation, 500 to 700 ng DNA was incubated using ONT Native Barcodes and Blunt/TA Ligase Master Mix (NEB) and purified using DNA Clean & Concentrator-5 columns 90 91 (Zymo Research). Purified, barcoded DNA samples for one sequencing run (between 92 4 to 8 samples, see Supplementary Table S1) were pooled equimolar in one tube 93 and ligated to AMII adapters (ONT) with NEBNext® Quick Ligation Reaction Buffer 94 and Quick T4 DNA Ligase (both NEB). For the final clean-up, 0.5x SPRIselect beads 95 (Beckman Coulter, USA) were utilized to ensure elimination of small DNA fragments and washed with Short Fragment Buffer (ONT) before elution. 96

97 Nanopore sequencing:

The sequencing-ready library was primed and loaded on a MinION R9.4 flow cell 98 99 (FLO-MIN106D, ONT) according to manufactures recommendation using 25-50 fmol 100 DNA library. Sequencing was performed on MinION Mk1C with simultaneous base 101 calling using standard base calling settings and quality threshold (minimum Q-score) 102 of 8. Sequencing time was adapted according to number of samples pooled and 103 quality of the flow cell (pores available) with average sequencing time of around 9 104 hours for 6 pooled PB samples resulting in a median number of 105,670 reads (after pre-processing, stdev= 76,444) and 210 Mbases (stdev=100) generated per sample 105 106 (detail sequencing constitution, time and output in Supplementary Table S1).

107 Data analysis:

Nanopore's *MinKNOW* software system controls the raw data acquisition, performing basecalling and demultiplexing with *Guppy* as well as FASTQ file creation. Following on, a data analysis pipeline was applied, developed for long read-based PGT-A data using standard bioinformatics tools and custom software scripts. The specific processing steps are described in the following.

113 Primary data analysis consisted of read cleaning with Porechop (Porechop, 114 RRID:SCR_016967) and Nanofilt (29), alignment to the human genome GRCh38 115 with minimap2 (30) and creation of BAM files with samtools (31). Secondary 116 processing steps made use of the QDNAseq R software package (32) and include 117 binning of reads using a custom 500 kb bin matrix, GC content and mappability 118 correction, median and reference normalisation, smoothing, segmentation and copy-119 number calling. A set of five samples were used as a combined reference to capture 120 experiment-specific bias. They represented the first few samples of the study with a 121 representative profile and without whole-chromosome copy-number changes as 122 assessed by aCGH. Further processing was performed to filter and summarize the data, producing a report with genome-wide copy-number plots, noise measurements
 and automatically detected changes per chromosome and sample. Samples with
 more than 3 aneuploid chromosomes were classified as 'multiple'.

As quality measures of the nanopore sequencing samples, MAPD (Median of the Absolute values of all Pairwise Differences) and noise (median standard deviation of normalised read counts within each segment) values are reported for all chromosomes as well as for each sample and automatically plotted in the chromosomal distribution plots. Samples resulting in a total noise value greater than 0.6 and MAPD value greater than 1.7 were excluded from the comparison (Supplementary Table S1).

133 **Results**

In this study, 102 pooled PB samples from 20 patients were analyzed for PGT-A by nanopore sequencing and compared to clinical routine PGT-A analysis by aCGH. All samples were successfully amplified while a negative control (culture medium) for each batch showed no amplification and aCGH was performed for all 102 PB samples. WGA aliquots were anonymized and used for nanopore sequencing. Schematic study design is shown in Figure 1.

140

141 Quality control and genome coverage for nanopore sequencing workflow:

In total three samples were excluded from the comparison. Two samples (PB61,
PB95) were excluded due to failed or uninterpretable aCGH (2 %) and one sample
(PB48, 1%) was excluded due to failed quality check after nanopore sequencing with
noise and MAPD values below quality threshold.

146 Data analysis from nanopore sequencing results revealed medium sequencing output of 210 Mbases and a median of 105,670 reads per sample (after pre-147 processing, 70 to 650 Mbases and 32,924 to 374,841 reads). A median of 3% (88 148 149 Mbases) of the genome was covered by one or more reads (between 0.9 - 9.3%). 150 With the 0.5 Mbases bin matrix applied in the analysis, a smoothing window of 6 bins 151 and a calling limit of 20 bins, the application has a theoretical resolution of around 10 152 Mbases. This is comparable with the common resolution for PGT-A using aCGH or 153 NGS (6-10 Mbases) (33). Average Q-score of all nanopore-sequenced samples was 154 8. Quality was additionally verified in the bioinformatic data analysis pipeline by noise 155 and MAPD values. Average noise of all samples was 0.428 (between 0.230 and 0.724) and average MAPD was 1.164 (between 0.720 and 1.809). All noise and 156

MAPD values are listed in Supplementary Table S1 and realtionship between bothquality measures is visualized in Supplementary Figure S1.

159

160 Comparison of PGT-A results from nanopore sequencing with routine aCGH results:

161 In total, 99 pooled PB samples for PGT-A screening were utilized in this study for 162 comparison of aCGH with nanopore sequencing workflow. From these, 29 were 163 detected euploid (29.3 %) and 70 were detected aneuploid (70.7 %) by aCGH reference. This is expected, given the patient cohort with medium female age of 40.5 164 165 years. Nanopore sequencing analysis detected 32 samples as euploid and 67 as 166 aneuploid resulting in 97.0 % sample-level concordance and a sensitivity of 0.957, 167 specificity of 1.0 with a positive predictive value (PPV) of 1.0 and a negative predictive value (NPV) of 0.906 (Figure 1). The results of all aCGH and nanopore 168 169 sequencing analyses are listed in Table 1. Three samples detected as aneuploid 170 using aCGH revealed an euploid chromosomal pattern using nanopore sequencing. All three samples showed a single aneuploid chromosome (+22, +19, -16, 171 172 respectively) by aCGH and these elevations or reductions were visible but below 173 threshold at nanopore sequencing, as listed in Supplementary Table S1.

In total, aCGH analysis detected 195 aneuploid chromosomes in the 99 samples, 174 175 with 98 trisomies and 97 monosomies covering all 23 chromosomes, shown in Figure 176 3. Counting the exact match (all chromosomes concordant but assigning "multiple" to 177 karyotypes with more than three aberrations), we found 91.9% (karyotype-level) 178 concordance (91 of 99 samples showing exact match), as listed in Table 1. On 179 chromosomal level, we found 98,7% concordance (2244 of 2273 chromosomes were concordantly identified as normal or abnormal). Sensitivity was 0.901, specificity 180 0.995, PPV 0.945 and NPV 0.991 per chromosome. Segmental changes were not 181

addressed in this study. Example chromosomal distribution plots of euploid and aneuploid detected samples, which are automatically created from bioinformatic data analysis pipeline after nanopore sequencing are shown in Figure 4.

To assist the physicians and patients in the process of decision-making, a further critical evaluation of euploid-detected PBs can be performed and marginal/borderline elevated or reduced chromosomes can be mentioned together with the euploid result in the clinical report. Here, we performed manual revision of all euploid-detected samples after nanopore sequencing and the additional information about slightly elevated or reduced chromosomes can be found in Supplementary Table S1.

191

192 Endonuclease digestion step:

193 As part of this study, we evaluated the importance of an endonuclease digestion 194 step. 28 samples were run in parallel with and without endonuclease digestion step. 195 While samples with a high signal to noise ratio show matching results, the additional 196 digestion clearly reduces noise and improves calling for challenging cases. Reduction 197 of average noise and MAPD values, as well as improvements of sequencing-output 198 per time is shown in Supplementary Figure S2. Detailed comparison of sequencing 199 results with and without endonuclease digest is listed in Supplementary Table S2. 200 For the calculation of concordance between aCGH and nanopore sequencing, results 201 after Endonuclease digest were utilized for all these samples. For all new 202 investigations we recommend adding this step.

203

204 Detailed time and cost calculation:

To evaluate if nanopore sequencing for PGT-A can be utilized in clinical routine, we performed a detailed time and cost analysis for our nanopore sequencing workflow, 207 which is listed in Supplementary Tables S3 and S4. The nanopore sequencing 208 workflow used in this study starting from amplified DNA until ploidy result is feasible 209 in one and a half hours with one sample being sequenced separately. For 12 samples being sequenced in parallel, the workflow is feasible in around 12 hours 210 211 (Supplementary Table S3). Amplification of the pooled PB additionally take between 212 1.5 hours and 4.5 hours per sample, depending on the WGA kit. In our study, WGA 213 was performed using REPLIg Single Cell Kit (QIAGEN) with a 2.5 h amplification 214 protocol.

Material cost for the whole workflow, including WGA, sample preparation, sequencing and data analysis range from 100€ to 220€ per sample. A detailed list of time and cost calculation for different scenarios is shown in Supplementary Table S3 and S4. Initial investment cost for nanopore sequencing can be neglected because prices for nanopore starter packages, where MinION sequencing machines are included cover material costs.

221

222 **Discussion**

223 The present study is the first study that systematically compares PB PGT-A analysis 224 using nanopore sequencing with routine aCGH analysis. The concordance rate 225 between both technologies found in this study was 97% for euploid/aneuploid sample 226 decision and 99% on chromosomal level. These concordance rates are high, given 227 the different nature of the methods and the delicate sample type of PB biopsy. Similar 228 studies comparing different technologies for PGT-A analysis received slightly higher 229 concordance rates (26,34-36). However, genetic material utilized in these studies 230 was originated from TEB, which comprises significantly more genetic starting material 231 than PB biopsy, resulting in more stable and uniform whole genome amplification. 232 From 102 PB samples analyzed with nanopore sequencing in our study, 101 samples 233 passed the quality threshold, indicating a high reliability of the technology.

234

235 Nanopore sequencing has several advantages, compared to aCGH or NGS analysis, 236 including but not limited to the fast turnaround time, inexpensive sequencing, as well 237 as small initial investment costs needed. These advantages might lead to cost-238 efficient diagnostics for clinical applications. Time and cost of nanopore sequencing 239 for clinical reproductive healthcare has been reported in several publications, but 240 detailed statements on how these number can be achieved are often not stated 241 (20,25,26,37). Here, we provide detailed insight in material costs and preparation, 242 sequencing, and data analysis time for different scenarios (Supplementary Table S3 243 and S4).

Another advantage of nanopore sequencing compared to aCGH or NGS is the high flexibility of the sequencing method. Sequencing data as well as quality measures of the data generated, and the flow cell health can be monitored in real-time during nanopore sequencing. If more data is required or quality of the library is poor, sequencing can easily be prolonged or repeated on the same flow cell until enough data is generated. This can reduce the necessity to repeat uninterpretable results and can reduce prolonged time-to diagnosis, increasing the possibility for same-cycle transfer of euploid embryos, leading again to a cost reduction by reducing freeze-all procedures and hormonal treatment for the embryo transfer, possibly leading to a shorter time-to-pregnancy.

254

255 A possible limitation of the study derives from the reference method. In a comparable 256 study using nanopore sequencing in comparison with standard clinical detection 257 methods (NGS, aCGH or fluorescence in situ hybridization, FISH), discordant 258 aneuploidy results were re-examined and the initial nanopore sequencing results 259 were confirmed in these samples, showing that even established clinical testing 260 methods like FISH or aCGH might result in misdiagnosis (26). Misdiagnosis of routine 261 aCGH PGT-A analysis has also been shown in a study comparing aCGH with NGS 262 results (35). In the present study using material from pooled PBs, re-examination of 263 aCGH was not possible due to limited sample resource.

264 For some samples in this study, the reference result remained unclear, due to 265 increased noise and limited resolution of the aCGH method. In particular, the small 266 chromosomes show higher variability in both platforms. Discordant results could 267 originate from different thresholds defined in aCGH and nanopore sequencing, 268 different analysis bias and bias reduction (in the nanopore workflow, bias was 269 reduced through binning, GC content and mappability correction, median and 270 reference normalisation), or different genome covargae and resolution. Although the 271 reference method has been extensively validated (5) and is applied in clinical routine since 2015, the utilization of pooled PBs, analyzed with aCGH might come with some technical limitations, including limited resolution and the necessity for manual revision. While the assessment and quantification of the nanopore sequencing results is clearer, manual review is still recommended and sometimes required. A larger study with follow-up data or a clinical non-selection trial would be beneficial for increased confidence.

Utilizing pooled PBs, compared to analyzing PB 1 and 2 separately, requires more sensitive detection methods, since variations from normal euploid chromosomes depict less distinct in pooled PBs. However, if properly validated (5), pooling PBs can considerably reduce the costs and the workload of the analysis.

282

283 Independent of the technology, the analysis of chromosomal material is complicated 284 by different characteristics of human chromosomes (38). The short chromosomes 285 19, 20, 21, 22 and Y provide limited material which leads to an increased variability in 286 measurements. The GC-richest chromosomes 16, 17, 19 and 22 often display increased levels of noise. Also, chromosomes with heterochromatic polymorphisms, 287 288 like chromosomes 1, 9 and 16 differ due to normal, benign variations in heterochromatin-content, which can be visualized by microscopy but are hard to 289 290 interpret in sequencing-based methods or aCGH (39). In our study, the 291 chromosomes 9, 19, 21 and 22 showed most discordances (Figure 3).

292

Although manual review of the chromosomal distribution of each sample is recommended, our data analysis pipeline automatically generates the sequencing plot with significantly abnormal chromosomes being highlighted and quality measures (noise and MAPD) are plotted for each chromosome. The karyotype is reported 297 automatically according to the optimized bioinformatic pipeline. This automation 298 together with the clear and easy-to-read karyotype plot makes the nanopore 299 sequencing data very easy to understand and interpret. Interpretation of the results 300 does not require years of expert knowledge and experience, which is often required 301 for the interpretation of aCGH plots. The automated analysis pipeline is not 302 dependent on subjective decision-making of the responsible geneticist or physician.

Nevertheless, following the clinical practice, we additionally performed manual review of all euploid-detected samples (Supplementary Table S1). This additional annotation about slight chromosomal aberrations does not change the automatically reported result (euploid) but can be provided as additional information in the medical report. This report can facilitate the embryo prioritization and decision-making for the physician and the patients as part of their fertility treatment.

309

Taken together, pooled PB nanopore sequencing revealed high concordance rates compared to conventional aCGH with minimized time and financial resources required.

Acknowledgements

We would like to thank all patients participating in this study. We also thank all staff members from HLN Genetic GmbH for providing the reference samples.

References

- Franasiak JM, Forman EJ, Hong KH, Werner MD, Upham KM, Treff NR, et al. The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. Fertil Steril 2014;101(3).
- 2. Petracchi F, Colaci DS, Igarzabal L, Gadow E. Cytogenetic analysis of first trimester pregnancy loss. Int J Gynaecol Obstet 2009;104(3):243–4.
- Fonseka KGL, Griffin DK. Is there a paternal age effect for aneuploidy?
 Cytogenet Genome Res 2011;133(2–4):280–91.
- Rubio C, Bellver J, Rodrigo L, Castillón G, Guillén A, Vidal C, et al. In vitro fertilization with preimplantation genetic diagnosis for aneuploidies in advanced maternal age: a randomized, controlled study. Fertil Steril 2017;107(5):1122–9.
- Feichtinger M, Stopp T, Göbl C, Feichtinger E, Vaccari E, Mädel U, et al. Increasing Live Birth Rate by Preimplantation Genetic Screening of Pooled Polar Bodies Using Array Comparative Genomic Hybridization. PLoS One 2015;10(5):e0128317.
- Cohen J, Wells D, Munné S. Removal of 2 cells from cleavage stage embryos is likely to reduce the efficacy of chromosomal tests that are used to enhance implantation rates. 2007;87(3):496–503.
- Scott RT, Upham KM, Forman EJ, Zhao T, Treff NR. Cleavage-stage biopsy significantly impairs human embryonic implantation potential while blastocyst biopsy does not: a randomized and paired clinical trial. Fertil Steril 2013;100(3):624–30.
- 8. Mastenbroek S, Twisk M, van Echten-Arends J, Sikkema-Raddatz B, Korevaar JC, Verhoeve HR, et al. In Vitro Fertilization with Preimplantation Genetic

Screening. N Engl J Med 2007;357(1):9–17.

- Viotti M, Victor AR, Barnes FL, Zouves CG, Besser AG, Grifo JA, et al. Using outcome data from one thousand mosaic embryo transfers to formulate an embryo ranking system for clinical use. Fertil Steril 2021;115(5):1212–24.
- Greco E, Minasi MG, Fiorentino F. Healthy Babies after Intrauterine Transfer of Mosaic Aneuploid Blastocysts. N Engl J Med 2015;373(21):2089–90.
- Treff NR, Marin D. The "mosaic" embryo: misconceptions and misinterpretations in preimplantation genetic testing for aneuploidy. Fertil Steril 2021;116(5):1205–11.
- Verpoest W, Staessen C, Bossuyt PM, Goossens V, Altarescu G, Bonduelle M, et al. Preimplantation genetic testing for aneuploidy by microarray analysis of polar bodies in advanced maternal age: a randomized clinical trial. Hum Reprod 2018;33(9):1767–76.
- Hengstschläger M, Feichtinger W. Die erste Präimplantationsdiagnostik in Österreich. Wien Klin Wochenschr 2005;117(21–22):725–7.
- Ven K van der, Montag M, Ven H van der. Polar Body Diagnosis A Step in The Right Direction? Dtsch Arztebl Int 2008;
- Neumann K, Griesinger G. An Economic Analysis of Aneuploidy Screening of Oocytes in Assisted Reproduction in Germany. Geburtshilfe Frauenheilkd 2020;80(2):172–8.
- Neumann K, Sermon K, Bossuyt P, Goossens V, Geraedts J, Traeger-Synodinos J, et al. An economic analysis of preimplantation genetic testing for aneuploidy by polar body biopsy in advanced maternal age. BJOG An Int J Obstet Gynaecol 2020;127(6):710–8.
- 17. Cabibbe AM, Spitaleri A, Battaglia S, Colman RE, Suresh A, Uplekar S, et al.

Application of Targeted Next-Generation Sequencing Assay on a Portable Sequencing Platform for Culture-Free Detection of Drug-Resistant Tuberculosis from Clinical Samples. J Clin Microbiol 2020;58(10).

- Amarasinghe SL, Su S, Dong X, Zappia L, Ritchie ME, Gouil Q. Opportunities and challenges in long-read sequencing data analysis. Genome Biol 2020;21(1).
- Jain M, Koren S, Miga KH, Quick J, Rand AC, Sasani TA, et al. Nanopore sequencing and assembly of a human genome with ultra-long reads. Nat Biotechnol 2018 364 2018;36(4):338–45.
- Cretu Stancu M, van Roosmalen MJ, Renkens I, Nieboer MM, Middelkamp S, de Ligt J, et al. Mapping and phasing of structural variation in patient genomes using nanopore sequencing. Nat Commun 2017;8(1):1326.
- Pei Z, Deng K, Lei C, Du D, Yu G, Sun X, et al. Identifying Balanced Chromosomal Translocations in Human Embryos by Oxford Nanopore Sequencing and Breakpoints Region Analysis. Front Genet 2022;0:2723.
- 22. Margolis C, Werner M, Jalas C. Variant haplophasing by long-read sequencing: proof of concept in preimplantation genetic workup and an opportunity to distinguish balanced and normal embryos. Fertil Steril 2021;116(3):668–9.
- Hu L, Liang F, Cheng D, Zhang Z, Yu G, Zha J, et al. Location of Balanced Chromosome-Translocation Breakpoints by Long-Read Sequencing on the Oxford Nanopore Platform. Front Genet 2019;10(January):1313.
- Madjunkova S, Sundaravadanam Y, Antes R, Abramov R, Chen S, Yin Y, et al. Detection of Structural Rearrangements in Embryos. N Engl J Med 2020;382(25):2472–4.
- 25. Wei S, Weiss ZR, Gaur P, Forman E, Williams Z. Rapid preimplantation

genetic screening using a handheld, nanopore-based DNA sequencer. Fertil Steril 2018;110(5):910-916.e2.

- Wei S, Djandji A, Lattin MT, Nahum O, Hoffman N, Cujar C, et al. Rapid Nanopore Sequencing-Based Screen for Aneuploidy in Reproductive Care. N Engl J Med 2022;387(7):658–60.
- Tan VJ, Liu T, Arifin Z, Pak B, Tan ASC, Wong S, et al. Third-Generation Single-Molecule Sequencing for Preimplantation Genetic Testing of Aneuploidy and Segmental Imbalances. Clin Chem 2023;00(0):1–9.
- Oberle A, Carli L, Ennemoser A, Hengstschläger M, Feichtinger M. P-533
 Single-cell long-read nanopore sequencing as a fast and cost-efficient method for aneuploidy detection and potentially PGT-A, a pre-clinical study. Hum Reprod 2022;37(Supplement_1).
- De Coster W, D'Hert S, Schultz DT, Cruts M, Van Broeckhoven C. NanoPack: visualizing and processing long-read sequencing data. Bioinformatics 2018;34(15):2666–9.
- Li H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 2018;34(18):3094–100.
- Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009;25(16):2078–9.
- 32. Scheinin I, Sie D, Bengtsson H, van de Wiel MA, Olshen AB, van Thuijl HF, et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res 2014;24(12):2022–32.

- 33. Snider AC, Darvin T, Spor L, Akinwole A, Cinnioglu C, Kayali R. Criteria to evaluate patterns of segmental and complete aneuploidies in preimplantation genetic testing for aneuploidy results suggestive of an inherited balanced translocation or inversion. F&S Reports 2021;2(1):72–9.
- Kung A, Munné S, Bankowski B, Coates A, Wells D. Validation of nextgeneration sequencing for comprehensive chromosome screening of embryos. Reprod Biomed Online 2015;31(6):760–9.
- Sachdeva K, Discutido R, Albuz F, Almekosh R, Peramo B. Validation of Next-Generation Sequencer for 24-Chromosome Aneuploidy Screening in Human Embryos. Genet Test Mol Biomarkers 2017;21(11):674–80.
- Walters-Sen L, Neitzel D, Bristow SL, Mitchell A, Alouf CA, Aradhya S, et al. Experience analyzing >190,000 embryo trophectoderm biopsies using a novel FAST-SeqS PGT assay. Reprod Biomed Online 2021;
- Bartalucci N, Romagnoli S, Contini E, Marseglia G, Magi A, Guglielmelli P, et al. Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing. Clin Chem 2019;65(12):1604–5.
- Piovesan A, Pelleri MC, Antonaros F, Strippoli P, Caracausi M, Vitale L. On the length, weight and GC content of the human genome. BMC Res Notes 2019;12(1):106.
- Hernandez-Nieto C, Gayete-Lafuente S, Alkon-Meadows T, Lee J, Luna-Rojas M, Mukherjee T, et al. Parental chromosomal heteromorphisms are not associated with an increased risk of embryo aneuploidy. JBRA Assist Reprod 2021;25(4):575–80.


Figure Legends:


Figure 1: Study design including concordance rates found in this study. WGA: whole-genome amplification; PGT-A: preimplantation-genetic testing for aneuploidy; aCGH: array comparative genomic hybridization; PPV and NPV: positive and negative predictive value.


Figure 2: Schematic overview of the nanopore sequencing workflow, including time measures for individual procedures, embedded in the clinical PGT-A workflow. Prorate sequencing time per sample was calculated according to medium sequencing time for 6 pooled samples. Separate sequencing of one sample can be shorter. ICSI: intra-cytoplasmatic sperm injection; PB: polar body; WGA: whole-genome amplification.


Figure 3: Occurrence of whole-chromosome aneuploidies in all 99 pooled PB samples. TP: true positive, FN: false negative, FP: false positive.

Figure 4: Example chromosomal distribution plots from automatically generated nanopore sequencing workflow. Quality values noise and MAPD are mapped for each chromosome and thresholds for the total sample (0.6 and 1.7, respectively) are highlighted in red. MAPD: Median of the Absolute values of all Pairwise Differences; noise: median standard deviation of normalised read counts within each segment.









Sample Number	aCGH	Ploidy Status	Concordanco	Ch aCGH	romosome Aberrat Nanopore	1
Pb1	aneuploid	Nanopore aneuploid	Concordance CONCORDANT	multiple	multiple	Concordance CONCORDANT
Pb2	aneuploid	aneuploid	CONCORDANT	+22	+22	CONCORDANT
Pb3	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb4	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb5	aneuploid	aneuploid	CONCORDANT	-1	-1	CONCORDANT
Pb6	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb7 Pb8	euploid euploid	euploid euploid	CONCORDANT	-	-	CONCORDANT
Pb9	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb10	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb11	aneuploid	aneuploid	CONCORDANT	-4	-4	CONCORDANT
Pb12	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb13	aneuploid	aneuploid	CONCORDANT	-15	-15	CONCORDANT
Pb14	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb15	aneuploid	aneuploid	CONCORDANT	-10, +14	-10, +14	CONCORDANT
Pb16 Pb17	aneuploid aneuploid	aneuploid aneuploid	CONCORDANT	+10, +X -14, +20	+10, +X -14, +20	CONCORDANT CONCORDANT
Pb18	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb19	aneuploid	aneuploid	CONCORDANT	+16, -18, -20	+16, -18, -20	CONCORDANT
Pb20	aneuploid	aneuploid	CONCORDANT	-7, +16	multiple	DISCORDANT
Pb21	aneuploid	aneuploid	CONCORDANT	+19, -21, -22	-21	DISCORDANT
Pb22	aneuploid	aneuploid	CONCORDANT	+12, -13, -16	+12, -13, -16	CONCORDANT
Pb23	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb24 Pb25	euploid euploid	euploid euploid	CONCORDANT	-	-	CONCORDANT
Pb26	aneuploid	aneuploid	CONCORDANT	-16	-16	CONCORDANT
Pb26 Pb27	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb28	aneuploid	aneuploid	CONCORDANT	-6, -12	-6, -12	CONCORDANT
Pb29	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb30	aneuploid	aneuploid	CONCORDANT	+11, +15, +22	+11, +15, +22	CONCORDANT
Pb31	aneuploid	aneuploid	CONCORDANT	-17	-17	CONCORDANT
Pb32	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb33	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb34 Pb35	aneuploid	aneuploid	CONCORDANT	-13, -15, -21	-13, -15, -21	CONCORDANT
Pb35 Pb36	aneuploid euploid	aneuploid euploid	CONCORDANT	-22	-22	CONCORDANT
Pb36 Pb37	aneuploid	aneuploid	CONCORDANT	+16	+16	CONCORDANT
Pb38	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb39	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb40	aneuploid	aneuploid	CONCORDANT	+4	+4	CONCORDANT
Pb41	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb42	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb43	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb44 Pb45	aneuploid aneuploid	aneuploid aneuploid	CONCORDANT	+15 +16, -19	+15 +16, -19	CONCORDANT
Pb45 Pb46	aneuploid	euploid	DISCORDANT	+10,-15		DISCORDANT
Pb47	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb48	euploid	not evaluable	EXCLUDED			EXCLUDED
			LACLODED	-		EXCLODED
Pb49	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb50	euploid	euploid euploid	CONCORDANT CONCORDANT	-	-	CONCORDANT CONCORDANT
Pb50 Pb51	euploid aneuploid	euploid euploid aneuploid	CONCORDANT CONCORDANT CONCORDANT	- - multiple	- - multiple	CONCORDANT CONCORDANT CONCORDANT
Pb50 Pb51 Pb52	euploid aneuploid euploid	euploid euploid aneuploid euploid	CONCORDANT CONCORDANT CONCORDANT CONCORDANT	- - multiple -	- - multiple -	CONCORDANT CONCORDANT CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53	euploid aneuploid euploid euploid	euploid euploid aneuploid euploid euploid	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT	-	-	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54	euploid aneuploid euploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT	- -9, -15	-9, -15	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53	euploid aneuploid euploid euploid aneuploid aneuploid	euploid euploid aneuploid euploid euploid	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT	-	-9,-15 -17,-18	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55	euploid aneuploid euploid euploid aneuploid	euploid euploid aneuploid euploid euploid aneuploid aneuploid	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT	- -9, -15 -17, -18	-9, -15	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56	euploid aneuploid euploid euploid aneuploid aneuploid aneuploid	euploid euploid aneuploid euploid euploid aneuploid aneuploid aneuploid	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT	- -9, -15 -17, -18	-9,-15 -17,-18	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb58 Pb59	euploid aneuploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid	euploid euploid aneuploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT	-9,-15 -17,-18 -16	-9,-15 -17,-18 -16	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT DISCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb58 Pb59 Pb59 Pb60	euploid aneuploid euploid euploid aneuploid aneuploid euploid aneuploid aneuploid euploid	euploid euploid aneuploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT	-9, -15 -17, -18 -16 -13, -14, +17	-9, -15 -17, -18 -16 multiple multiple	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT DISCORDANT CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb58 Pb59 Pb59 Pb60 Pb61	euploid aneuploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid not evaluable	euploid euploid aneuploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT EXCLUDED	-9, -15 -17, -18 -16 -13, -14, +17 multiple		CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT DISCORDANT CONCORDANT CONCORDANT EXCLUDED
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb58 Pb59 Pb60 Pb61 Pb62	euploid aneuploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid not evaluable aneuploid	euploid euploid aneuploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT EXCLUDED DISCORDANT	-9, -15 -17, -18 -16 -13, -14, +17 multiple +19	-9, -15 -17, -18 -16 multiple multiple	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT EXCLUDED DISCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb58 Pb59 Pb60 Pb61 Pb62 Pb63	euploid aneuploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid	euploid euploid aneuploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT EXCLUDED DISCORDANT CONCORDANT	-9,-15 -17,-18 -16 	-9,-15 -17,-18 -16 	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT DISCORDANT CONCORDANT CONCORDANT EXCLUDED DISCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb58 Pb59 Pb60 Pb61 Pb62	euploid aneuploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid not evaluable aneuploid	euploid euploid aneuploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT EXCLUDED DISCORDANT	-9, -15 -17, -18 -16 -13, -14, +17 multiple +19	-9, -15 -17, -18 -16 multiple multiple	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT EXCLUDED DISCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb58 Pb59 Pb59 Pb60 Pb61 Pb62 Pb63 Pb64	euploid aneuploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid not evaluable aneuploid aneuploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid aneuploid aneuploid aneuploid	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT EXCLUDED DISCORDANT CONCORDANT CONCORDANT	-9,-15 -17,-18 -16 -13,-14,+17 multiple +19 multiple +4	-9,-15 -17,-18 -16 	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT DISCORDANT DISCORDANT EXCLUDED DISCORDANT CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb58 Pb59 Pb60 Pb60 Pb61 Pb62 Pb63 Pb64 Pb65	euploid aneuploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid	euploid euploid aneuploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT EXCLUDED DISCORDANT CONCORDANT CONCORDANT CONCORDANT			CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT EXCLUDED DISCORDANT CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb55 Pb56 Pb57 Pb58 Pb59 Pb50 Pb60 Pb61 Pb62 Pb63 Pb64 Pb65 Pb65 Pb65 Pb66 Pb67 Pb68	euploid aneuploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid	euploid euploid aneuploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT			CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb57 Pb56 Pb57 Pb59 Pb59 Pb60 Pb61 Pb62 Pb62 Pb64 Pb65 Pb64 Pb65 Pb66 Pb66 Pb66 Pb68 Pb69	euploid aneuploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid not evaluable aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT EXCLUDED DISCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb54 Pb54 Pb55 Pb56 Pb57 Pb58 Pb59 Pb59 Pb60 Pb61 Pb62 Pb63 Pb64 Pb64 Pb65 Pb66 Pb67 Pb68 Pb69 Pb70	euploid aneuploid euploid euploid aneuploid aneuploid aneuploid euploid aneuploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid	euploid euploid aneuploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT EXCLUDED DISCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT			CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT OCNCORDANT DISCORDANT CONCORDANT EXCLUDED DISCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb56 Pb57 Pb58 Pb59 Pb60 Pb57 Pb60 Pb61 Pb62 Pb63 Pb64 Pb65 Pb66 Pb66 Pb66 Pb66 Pb67 Pb68 Pb59 Pb57 Pb57	euploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb58 Pb59 Pb60 Pb61 Pb62 Pb63 Pb63 Pb64 Pb63 Pb64 Pb65 Pb66 Pb65 Pb66 Pb66 Pb67 Pb68 Pb57 Pb57 Pb57	euploid aneuploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid not evaluable aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid aneuploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT
Pb50 Pb51 Pb53 Pb53 Pb54 Pb55 Pb56 Pb57 Pb59 Pb59 Pb60 Pb61 Pb62 Pb63 Pb64 Pb63 Pb64 Pb65 Pb66 Pb67 Pb68 Pb69 Pb57 Pb59 Pb57 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59	euploid aneuploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT OCNCORDANT DISCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb58 Pb59 Pb60 Pb61 Pb62 Pb63 Pb63 Pb64 Pb63 Pb64 Pb65 Pb66 Pb66 Pb66 Pb66 Pb66 Pb67 Pb68 Pb57 Pb57 Pb57	euploid aneuploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid not evaluable aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT
Pb50 Pb51 Pb53 Pb53 Pb54 Pb55 Pb55 Pb57 Pb58 Pb59 Pb60 Pb61 Pb62 Pb63 Pb64 Pb63 Pb64 Pb65 Pb64 Pb65 Pb66 Pb66 Pb67 Pb68 Pb69 Pb71 Pb72 Pb72 Pb74	euploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb55 Pb55 Pb55 Pb55 Pb56 Pb58 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59	euploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb55 Pb55 Pb55 Pb55 Pb56 Pb59 Pb59 Pb50 Pb61 Pb62 Pb63 Pb62 Pb63 Pb64 Pb65 Pb65 Pb66 Pb65 Pb56 Pb56 Pb57 Pb72 Pb73 Pb77 Pb77 Pb78	euploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb59 Pb50 Pb50 Pb50 Pb50 Pb62 Pb62 Pb63 Pb64 Pb64 Pb64 Pb64 Pb65 Pb64 Pb66 Pb67 Pb68 Pb57 Pb58 Pb57 Pb78 Pb75 Pb78 Pb79 Pb78 Pb79	euploid aneuploid euploid aneuploid aneuploid aneuploid aneuploid euploid aneuploid euploid aneuploid	euploid euploid aneuploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT	-9, -15 -17, -18 -16 -13, -14, +17 multiple +19 multiple +4 +16 -10, -22 +11, -15 +2 +6, -18 -16, -22 +11, +19, -17 -16, +21 +4, -20 -16, +21 +16, +22 +18		CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT DISCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb55 Pb55 Pb55 Pb55 Pb55 Pb56 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59	euploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb55 Pb55 Pb55 Pb55 Pb55 Pb56 Pb59 Pb59 Pb59 Pb60 Pb61 Pb62 Pb63 Pb64 Pb65 Pb65 Pb66 Pb67 Pb58 Pb59 Pb71 Pb72 Pb73 Pb77 Pb77 Pb77 Pb77 Pb77 Pb77 Pb77	euploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb59 Pb50 Pb50 Pb62 Pb62 Pb62 Pb62 Pb63 Pb64 Pb65 Pb66 Pb65 Pb66 Pb67 Pb70 Pb73 Pb73 Pb75 Pb75 Pb78 Pb79 Pb79 Pb81 Pb81 Pb81 Pb81	euploid aneuploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT	-9, -15 -17, -18 -16 -13, -14, +17 multiple +19 multiple +4 +16 -16, -22 +11, +15, -15 +2 +6, -18 -16, -22 +11, +19, -17 -16, +21 +4, -20 -16, +21 +19, -13		CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT DISCORDANT OCNCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb55 Pb55 Pb55 Pb55 Pb55 Pb56 Pb59 Pb59 Pb59 Pb60 Pb61 Pb62 Pb63 Pb64 Pb65 Pb65 Pb66 Pb67 Pb58 Pb59 Pb71 Pb72 Pb73 Pb77 Pb77 Pb77 Pb77 Pb77 Pb77 Pb77	euploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb55 Pb55 Pb55 Pb55 Pb55 Pb56 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59	euploid aneuploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT DISCORDANT OCNCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb55 Pb55 Pb56 Pb57 Pb59 Pb59 Pb59 Pb59 Pb59 Pb50 Pb50 Pb61 Pb62 Pb62 Pb63 Pb64 Pb65 Pb65 Pb65 Pb65 Pb65 Pb56 Pb57 Pb58 Pb57 Pb77 Pb77 Pb77 Pb77 Pb77 Pb77 Pb77	euploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb59 Pb59 Pb50 Pb62 Pb62 Pb62 Pb63 Pb64 Pb65 Pb65 Pb65 Pb66 Pb65 Pb66 Pb69 Pb70 Pb73 Pb73 Pb77 Pb77 Pb77 Pb77 Pb77 Pb77	euploid aneuploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT	-9, -15 -17, -18 -16 -13, -14, +17 multiple +19 multiple +4 +16 -16, -22 +11, +16, -12 -16, -22 +11, +19, -17 -16, +21 -16, -10 -16 -16	9, -15 -17, -18 -16 	CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT CONCORDANT DISCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb55 Pb55 Pb55 Pb55 Pb55 Pb56 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59	euploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb55 Pb55 Pb55 Pb55 Pb56 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59	euploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb52 Pb53 Pb55 Pb55 Pb56 Pb58 Pb59 Pb59 Pb50 Pb59 Pb50 Pb50 Pb50 Pb50 Pb50 Pb50 Pb50 Pb50	euploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb59 Pb50 Pb50 Pb50 Pb50 Pb61 Pb62 Pb62 Pb63 Pb64 Pb62 Pb65 Pb66 Pb65 Pb66 Pb65 Pb66 Pb65 Pb66 Pb57 Pb58 Pb71 Pb72 Pb73 Pb74 Pb77 Pb77 Pb77 Pb77 Pb77 Pb77 Pb77	euploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb55 Pb55 Pb56 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59 Pb59	euploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb55 Pb56 Pb58 Pb59 Pb59 Pb50 Pb59 Pb50 Pb50 Pb50 Pb50 Pb50 Pb50 Pb50 Pb50	euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb55 Pb55 Pb55 Pb56 Pb57 Pb59 Pb50 Pb60 Pb61 Pb62 Pb62 Pb63 Pb64 Pb65 Pb66 Pb67 Pb68 Pb69 Pb71 Pb72 Pb73 Pb74 Pb77 Pb77 Pb77 Pb77 Pb77 Pb77 Pb77	euploid aneuploid euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid euploid euploid aneupl	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb59 Pb50 Pb50 Pb62 Pb62 Pb62 Pb63 Pb64 Pb65 Pb65 Pb65 Pb66 Pb67 Pb70 Pb70 Pb73 Pb74 Pb77 Pb77 Pb77 Pb77 Pb77 Pb77 Pb77	euploid aneuploi	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid aneuploid euploid euploid an	CONCORDANT CONCORDANT		9, -15 -17, -18 -16 -16 -17 -16 -17 -18 -16 -2 -10 -10 -10 -10 -10 -2 -10 -2 -10 -2 -10 -2 -10 -2 -10 -2 -10 -2 -10 -2 -10 -2 -10 -2 -10 -2 -10 -2 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10	CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb52 Pb53 Pb55 Pb55 Pb56 Pb58 Pb59 Pb59 Pb59 Pb50 Pb59 Pb50 Pb59 Pb50 Pb50 Pb50 Pb50 Pb50 Pb50 Pb50 Pb50	euploid aneuploi	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid an	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb59 Pb50 Pb50 Pb62 Pb62 Pb62 Pb63 Pb64 Pb65 Pb65 Pb65 Pb66 Pb67 Pb70 Pb70 Pb73 Pb74 Pb77 Pb77 Pb77 Pb77 Pb77 Pb77 Pb77	euploid aneuploi	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid aneuploid euploid euploid an	CONCORDANT CONCORDANT		9, -15 -17, -18 -16 -16 -17 -16 -17 -18 -16 -2 -10 -10 -10 -10 -10 -2 -10 -2 -10 -2 -10 -2 -10 -2 -10 -2 -10 -2 -10 -2 -10 -2 -10 -2 -10 -2 -10 -2 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10	CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb58 Pb50 Pb50 Pb60 Pb61 Pb62 Pb63 Pb64 Pb65 Pb65 Pb65 Pb65 Pb65 Pb65 Pb65 Pb65	euploid aneuploi	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid euploid aneu	CONCORDANT CONCORDANT		9, -15 -17, -18 -16 	CONCORDANT CONCORDANT
Pb50 Pb51 Pb52 Pb53 Pb54 Pb55 Pb56 Pb57 Pb59 Pb50 Pb50 Pb62 Pb62 Pb62 Pb62 Pb63 Pb64 Pb65 Pb65 Pb65 Pb65 Pb65 Pb65 Pb65 Pb65	euploid aneuploid	euploid euploid euploid euploid euploid aneuploid aneuploid aneuploid aneuploid euploid euploid euploid aneuploid	CONCORDANT CONCORDANT			CONCORDANT CONCORDANT